DGKA and neoplasm: The ability to limit T-cell activation in the tumor microenvironment, along with the promotion of tumor survival resulting from PA generation (10), are a tandem that underlie the challenges of therapeutic development in cancer, and present an opportunity for targeting DGKα in this context.